Related Experiment Videos
[Pediatric Mediterranean spotted fever]
J-M Garnier1, A-L Jurquet, K Retornaz
1Service de Pédiatrie, CHU Nord, chemin des Bourrelly, 13015 Marseillle. jean-marc.garnier@ap-hm.fr
Abstract:
In France, Mediterranean spotted fever due to Rickettsia conorii is mainly observed in the South-east. Rhipicephalus sanguineus, the brown dog tick, is the vector and the reservoir of the disease. Clinical diagnosis relies on the association of fever, rash and inoculation's scar during summertime. Pathological lesion is a diffuse vasculitis. Severity is often explained by a delay in diagnosis, but prognosis is good in pediatrics. Treatment relies on doxycycline and on macrolids in children under eight.
Insights
Mediterranean spotted fever, caused by Rickettsia conorii transmitted by the brown dog tick, is prevalent in Southeastern France. Early diagnosis and treatment with doxycycline are crucial for good outcomes, especially in children.
Area of Science:
- Infectious Diseases
- Epidemiology
- Dermatology
Context:
- Mediterranean spotted fever (MSF) is primarily diagnosed in Southeastern France.
- The brown dog tick (Rhipicephalus sanguineus) serves as both the vector and reservoir for Rickettsia conorii.
Purpose:
- To outline the epidemiological characteristics, clinical presentation, and management of MSF in France.
- To highlight diagnostic criteria and treatment options for MSF.
Summary:
- MSF diagnosis in France involves fever, rash, and an inoculation scar during summer.
- Pathological findings include diffuse vasculitis; delayed diagnosis can increase severity.
- Pediatric prognosis is generally favorable with prompt treatment.
Impact:
- Emphasizes the importance of timely diagnosis for improving patient outcomes in MSF cases.
- Provides guidance on appropriate antibiotic therapy, including doxycycline and macrolides for pediatric patients under eight.
Related Concept Videos
Rocky Mountain Spotted Fever
Leishmaniasis
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Antiprotozoal Agents
Fungal Phylum Microsporidia
Pharmacokinetics in Pediatric Patients: Drug Excretion